A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.
Cascade Pharmaceuticals, Inc. is advancing CS060380 in a Phase II trial to evaluate its efficacy and safety in combination with semaglutide for treating MASH and obesity. The market for obesity and related liver diseases is significant, with increasing prevalence globally. The combination therapy approach may provide a competitive edge against existing treatments, particularly as semaglutide has shown promise in weight management. Successful trial outcomes could position Cascade favorably in a growing market, but diligence is required regarding regulatory pathways and potential competition from other obesity and liver disease therapies.
Indication: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Modality: small molecule
Target: CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Sponsor: Cascade Pharmaceuticals, Inc
Source URL: ClinicalTrials.gov
Source updated: May 20, 2026
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
View original source fields
Condition raw: Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Condition normalized: Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Target normalized: CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.